__


We are analytics-driven,
technical problem-solvers
who have dedicated our lives
to developing biologics.


__

 

Global Leadership

KBI_Dirk_Lange

 

Dirk Lange

President and CEO

 

Doris Michor

 

Doris Michor

Executive VP, Operations

nophoto

 

Mark Roache

Senior VP, Quality & Regulatory

 

KBI_Stewart_McNaull

 

Stewart McNaull, Ph.D.

Senior VP, Business Development

KBI_Wayne_Yount

 

Wayne Yount, Ph.D.

Senior VP, Analytical & Formulation Sciences

 

Louise_Hall_web

 

Louise Hall

VP, Program Management

 

KBI_Rachel_Mandell

 

Rachel Mandell

VP and General Counsel

 

joey_mcmahon_web

 

Joey McMahon

VP, Impact Investment

 

KBI_Dan_Povia

 

Dan Povia

VP, Finance

 

KBI_Joe_Tetzlaff

 

Joe Tetzlaff

VP, Information Technology

 

Operations Leadership

Analytical and Formulation Sciences

Vicki_Dowling_Web

 

Vickie Dowling, Ph.D.

VP, Analytical & Formulation Sciences

Boulder, CO
KBI_John_Gabrielson

 

John Gabrielson, Ph.D.

VP, Analytical Sciences & Site Head

Louisville, CO
KBI_Brent_Kendrick

 

Brent Kendrick, Ph.D.

VP, Research & Development

Louisville, CO

 

Mammalian - North Carolina

KBI_Sigma_Mostafa

 

Sigma Mostafa, Ph.D.

VP, Process Development

RTP, NC
KBI_Carnley_Norman

 

Carnley Norman, Ph.D.

VP, Manufacturing Operations

Durham, NC
KBI_Tom_Milici

 

Thomas Milici

VP, Engineering

Durham, NC

Microbial - Colorado

Sandra_Lueken_web

 

Sandra Lueken

VP, Quality Operations

Boulder, CO
bob_todd_web

 

Bob Todd, Ph.D.

VP, Process Development

Boulder, CO

Cell Therapy - Texas

don_healey_web

 

Don Healey, Ph.D.

Senior VP and Site Head

The Woodlands, TX
lauren_collison_web

 

Lauren Collison, Ph.D.

VP, Process Analytical and QC

The Woodlands, TX
Mark Lutgen

 

Mark Lutgen

VP, Engineering

The Woodlands, TX

Joint Scientific Advisory Board

 

 
Background

In late 2018, KBI Biopharma, Inc. and Selexis SA announced the appointment of leading, internationally recognized scientists to a newly formed Joint Scientific Advisory Board (JSAB).

Formed to foster innovation in technology platforms used to bring complex molecules to clinic and ultimately to market, the JSAB offers unparalleled scientific and business expertise with three notable appointments: John F. Carpenter, Ph.D., Steven M. Cramer, Ph.D., and Michael J. Betenbaugh, Ph.D.

Our JSAB appointed members are experts in gene expression, cell line development, protein purification, analytics, and development of monoclonal antibodies and therapeutic proteins.
View Press Release

 

 

Appointed Members

 


John F. Carpenter, Ph.D.

Dr. Carpenter is Professor of Pharmaceutical Sciences at the University of Colorado School of Pharmacy, and a co-founder and co-director of the University of Colorado Center for Pharmaceutical Biotechnology. His research interests include mechanisms for protein degradation and stabilization in pharmaceutical formulations during bioprocessing and in delivery systems. Also, he has worked for several years to define rational strategies for stabilizing proteins and vaccines during freeze-drying and storage in the dried solid. He has published more than 280 peer-reviewed papers and is an inventor on more than 30 issued patents. He is editor for reviews and commentaries for Journal of Pharmaceutical Sciences. Dr. Carpenter serves on the editorial advisory boards for Pharmaceutical Research, The AAPS Journal, Journal of Pharmaceutical Sciences, Current Pharmaceutical Biotechnology, Molecular Pharmaceutics and BioPharm International. He has received several teaching awards and The Ebert Prize. He is a fellow of the American Association for Advancement of Science (AAS), the American Association of Pharmaceutical Scientists (AAPS) and the National Academy of Inventors. He has received the AAPS Research Achievement Award in Biotechnology. Dr. Carpenter also is the organizer of the Colorado Protein Stability Conferences. 

Steven M. Cramer, Ph.D.

 

Dr. Cramer is the William Weightman Walker Professor at Rensselaer Polytechnic Institute and is known for his contributions to the separation of complex biological products and the development of chromatographic materials, processes and predictive tools for enabling their biomanufacturing. In addition, he has made seminal contributions to the molecular understanding of the interactions that create unique selectivities in these separation systems. His lab is currently conducting research on several areas related to protein-surface interactions including prediction of protein binding affinity and multiscale modeling of chromatographic systems, development of efficient antibody and bispecific antibody separation systems, fundamental studies in multimodal chromatography, multilevel automated peptide synthesis/screening system for design of affinity peptides, smart biopolymer affinity precipitation systems, biophysics of protein interactions with surfaces, ligands and proteins, platformable strategies for effective removal of process HCPs and integrated semi-continuous biomanufacturing processes. He was the editor of Separation Science and Technology for 20 years and has been awarded the Alan S. Michaels Award for the Recovery of Biological Products (ACS Division of Biochemical Technology) and the ACS National Award in Separation Science and Technology. He was also awarded Rensselaer’s Early Career Award as well as the School of Engineering Outstanding Professor and Research Excellence Awards. Dr. Cramer has been elected a fellow of the American Association for the Advancement of Science, American Institute of Chemical Engineers, the American Chemical Society and the American Institute for Medical and Biological Engineering. 

Michael J. Betenbaugh, Ph.D.

Dr. Betenbaugh, an independent consultant as well as professor of chemical and biomolecular engineering and lead principal investigator of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC) at Johns Hopkins University, is known for integrating systems biology with cellular, metabolic and biochemical engineering for eukaryotic biotechnology applications. Dr. Betenbaugh is one of the original pioneers of eukaryotic metabolic engineering and has made multiple landmark contributions in improving the efficiency and effectiveness of mammalian and insect production hosts, in fundamental discoveries in glycobiology, in applying systems biology to understand mammalian cells in biotechnology and biomedicine and in advancing knowledge about sustainable algal bioprocessing for biofuels and other products. Dr. Betenbaugh’s most significant achievements include the application of chaperones and foldases to increase protein folding and product yields from insect cells; glycoengineering in insect and mammalian hosts to produce sialylated high-value glycoproteins; anti-apoptosis engineering to increase mammalian survival and productivity; genomics, proteomics, glycomics, and systems biology models of mammalian hosts; microRNA analysis and genome engineering in mammalian cells; and advancing sustainable microalgae processing. Dr. Betenbaugh’s group was the first to undertake whole pathway metabolic engineering to overcome glycosylation bottlenecks in one of the first projects funded as part of National Science Foundation’s Metabolic Engineering Program, a forerunner to current synthetic biology efforts. His group was also one of the first to demonstrate apoptosis activation in industrial cell culture processes and is the world leader in controlling programmed death in cell culture processes. Dr. Betenbaugh received the D.I.C. Wang Award for Excellence in Biochemical Engineering (2017), the Marvin J. Johnson (2015) and James Van Lanen awards from the American Chemical Society’s Division of Biochemical Technology and the Cell Culture Engineering Award (2010). He served as a visiting scientist at the Kyoto Institute of Technology in 2001 and is an elected fellow of the American Institute for Medical and Biological Engineering (AIMBE).